TMaga
4 days ago
Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC and/or OTCDNS. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to the risk that we will not be able to find and secure construction contracts and the necessary assets that will enable us to become profitable. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC and/or OTCDNS filings. We have incurred and will continue to incur significant expenses in our development stage, noting that there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. New lines of business in the construction industry may expose us to additional legal and regulatory costs and unknown exposure(s), the impact of which cannot be predicted at this time. Words such as "estimate," "project," "predict," "will," "would," "should," "could," "may," "might," "anticipate," "plan," "intend," "believe," "expect," "aim," "goal," "target," "objective," "likely" or similar expressions that convey the prospective nature of events or outcomes generally indicate forward-looking statements. You should not place undue reliance on these forward-looking statements, which speak only as of this press release. Unless legally required, we undertake no obligation to update, modify or withdraw any forward-looking statements, because of new information, future events or otherwise.
Viewmont
1 week ago
$ADHC The Breakthrough Devices Program is intended to provide patients and health care providers with timely access to medical devices by speeding up development, assessment, and review for premarket approval, 510(k) clearance, and De Novo marketing authorization. Breakthrough Devices must meet the FDA's rigorous standards for device safety and effectiveness in order to be authorized for marketing. The Breakthrough Devices Program reflects the FDA's commitment to device innovation and protecting the public health.
"We have received initial feedback back from the FDA indicating the application is qualified for review, we expect to hear back with comments from the reviewer in the near future and are optimistic that the GlucoGuard technology presents a compelling case for approval," commented the GlucoGuard team.
This FDA application combined with the recent announcement regarding Continuous Glucose Monitoring (CGM) with development partner Dexcomm has moved the development of this technology along rapidly. More negotiations with Investment Partners are in place and shareholders will be informed in the near future.
trader_ron
4 weeks ago
Adding on the dip, like money in the bank! $ADHC - Revolutionizing Health and Longevity with AI
Embrace a Healthier Future with Universal Wellness AI
At Universal Wellness AI, we harness the power of artificial intelligence to guide you on a journey to optimal health and longevity. Our cutting-edge research in modalities, algorithms, bio-device innovations, and app-based connectivity tools is designed to drive positive patient outcomes seamlessly. Whether you are recovering from a disease or taking a preventative approach to healthy living, Universal Wellness AI is your trusted partner.
$ADHC Stock Quotes-
https://www.otcmarkets.com/stock/ADHC/overview